(VIANEWS) – NEOEN (NEOEN.PA), NAVAMEDIC (NAVA.OL), PARETO BANK (PARB.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NEOEN (NEOEN.PA)
48.5% sales growth and 7.39% return on equity
Neoen S.A., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. The company operates through Solar Power, Wind Power, Storage, Farm-Down, Development and Investments, and Eliminations segments. It operates in Argentina, Australia, Canada, Ecuador, the United States, Finland, France, Ireland, Italy, Jamaica, Mexico, Mozambique, Portugal, El Salvador, Sweden, and Zambia. Neoen S.A. was incorporated in 2008 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, NEOEN has a trailing twelve months EPS of €1.13.
PE Ratio
NEOEN has a trailing twelve months price to earnings ratio of 21.79. Meaning, the purchaser of the share is investing €21.79 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.39%.
Volume
Today’s last reported volume for NEOEN is 29974 which is 77.75% below its average volume of 134759.
Revenue Growth
Year-on-year quarterly revenue growth grew by 23.6%, now sitting on 556.1M for the twelve trailing months.
Moving Average
NEOEN’s value is way below its 50-day moving average of €27.75 and way below its 200-day moving average of €27.59.
More news about NEOEN.
2. NAVAMEDIC (NAVA.OL)
20.7% sales growth and 11.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 32.54. Meaning, the purchaser of the share is investing kr32.54 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
Volume
Today’s last reported volume for NAVAMEDIC is 11231 which is 6.71% above its average volume of 10524.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr38.40 at 01:20 EST, way below its 52-week high of kr43.90 and way above its 52-week low of kr31.00.
Sales Growth
NAVAMEDIC’s sales growth is 19% for the ongoing quarter and 20.7% for the next.
More news about NAVAMEDIC.
3. PARETO BANK (PARB.OL)
15.7% sales growth and 13.76% return on equity
Pareto Bank ASA provides various banking products and services in Norway. The company accepts corporate deposits. It also offers corporate financing; receivables financing; residential and commercial financing for land and property; ship financing, including corporate and project financing; and other private or housing loans. Pareto Bank ASA was incorporated in 2007 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, PARETO BANK has a trailing twelve months EPS of kr7.75.
PE Ratio
PARETO BANK has a trailing twelve months price to earnings ratio of 7.17. Meaning, the purchaser of the share is investing kr7.17 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.76%.
Yearly Top and Bottom Value
PARETO BANK’s stock is valued at kr55.60 at 01:20 EST, below its 52-week high of kr59.50 and way above its 52-week low of kr48.55.
Sales Growth
PARETO BANK’s sales growth is 20.2% for the current quarter and 15.7% for the next.
More news about PARETO BANK.
4. SATS (SATS.OL)
10.1% sales growth and 3.89% return on equity
Sats ASA provides fitness and training services in Norway, Sweden, Denmark, and Finland. The company offers sportswear, fitness gear, bars, and energy drinks. It operates 275 fitness clubs under the SATS, ELIXIA, Fresh Fitness, SATSonline and SATSYoga brands. The company was founded in 1995 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, SATS has a trailing twelve months EPS of kr0.17.
PE Ratio
SATS has a trailing twelve months price to earnings ratio of 110.24. Meaning, the purchaser of the share is investing kr110.24 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.89%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SATS’s EBITDA is 20.14.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.4%, now sitting on 4.59B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 108.1% and a drop 12.9% for the next.
More news about SATS.
